Home
CMPS
CMPS News

Latest COMPASS Pathways Plc American Depository Shares (CMPS) News on November 20, 2025

Market Exclusive

18 days ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression

PR Newswire

21 days ago

NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression

COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 32% stake

Simply Wall St.

a month ago

COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 32% stake

As setbacks plague other companies, MindMed becomes a front-runner in the psychedelics race

Pharma Voice

a month ago

As setbacks plague other companies, MindMed becomes a front-runner in the psychedelics race

Compass’ stock slips despite psilocybin trial hitting target

Clinical Trials Arena

5 months ago

Compass’ stock slips despite psilocybin trial hitting target

Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial

Bloomberg

5 months ago

Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial

Compass’ big psychedelic study doesn’t impress investors

BioPharma Dive

5 months ago

Compass’ big psychedelic study doesn’t impress investors

MT Newswires

5 months ago

Compass Pathways' COMP360 Psilocybin for Depression Treatment Meets Primary Endpoint in Phase 3 Trial

Business Wire

5 months ago

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Trump Trade: President said to weigh possible U.S. strike against Iran

TipRanks

5 months ago

Trump Trade: President said to weigh possible U.S. strike against Iran

Psychedelic advocates hopeful Trump administration will support space, STAT says

TipRanks

5 months ago

Psychedelic advocates hopeful Trump administration will support space, STAT says

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Newsfile

5 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know

Zacks

6 months ago

COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know

Business Wire

6 months ago

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

TipRanks

6 months ago

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

Compass Pathways PLC (CMPS) Q1 2025 Earnings Call Highlights: Pivotal Phase 3 Trial Milestone ...

GuruFocus.com

6 months ago

Compass Pathways PLC (CMPS) Q1 2025 Earnings Call Highlights: Pivotal Phase 3 Trial Milestone ...

Business Wire

6 months ago

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Business Wire

7 months ago

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Business Wire

7 months ago

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Market Exclusive

7 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Why Compass Pathways Stock Was a Double-Digit Winner This Week

Motley Fool

7 months ago

Why Compass Pathways Stock Was a Double-Digit Winner This Week

Psychedelic: Clearmind completes clinical site initiations for AUD trial

TipRanks

7 months ago

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Business Wire

7 months ago

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Business Wire

8 months ago

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks

8 months ago

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai Life Sciences, NRx report quarterly results

TipRanks

8 months ago

Psychedelic: atai Life Sciences, NRx report quarterly results

Business Wire

8 months ago

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Business Wire

8 months ago

Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass one of the most compelling stories in neuropsych, says H.C. Wainwright

TipRanks

9 months ago

Compass one of the most compelling stories in neuropsych, says H.C. Wainwright

COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025

Insider Monkey

9 months ago

COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025

Psychedelic: GH Research, Compass Pathways report earnings results

TipRanks

9 months ago

Psychedelic: GH Research, Compass Pathways report earnings results

Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ...

GuruFocus.com

9 months ago

Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ...

Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript

Motley Fool

9 months ago

Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript

MT Newswires

9 months ago

Stifel Nicolaus Initiates Coverage on COMPASS Pathways With Buy Rating, $11 Price Target

Business Wire

9 months ago

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Business Wire

9 months ago

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Business Wire

9 months ago

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

Investor's Business Daily

9 months ago

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.

Investor's Business Daily

9 months ago

RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.

Business Wire

9 months ago

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Business Wire

10 months ago

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

MT Newswires

10 months ago

Compass Pathways Prices Offering of American Depositary Shares, Pre-Funded Warrants

Business Wire

10 months ago

Compass Pathways Announces Pricing of Underwritten Offering

MT Newswires

a year ago

Compass Pathways Shares Will Be Added to Nasdaq Biotechnology Index

Business Wire

a year ago

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

Motley Fool

a year ago

Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

Business Wire

a year ago

Compass Pathways to Participate in December Investor Conferences

COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stake

Simply Wall St.

a year ago

COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stake

Compass Pathways to participate in Stifel 2024 Healthcare Conference

GlobeNewswire

a year ago

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways cuts 30% of workforce on Phase 3 trial delays

TipRanks

a year ago

Compass Pathways cuts 30% of workforce on Phase 3 trial delays

Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

GuruFocus.com

a year ago

Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript

Motley Fool

a year ago

Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript

Compass delays anticipated psilocybin readout, cuts staff

BioPharma Dive

a year ago

Compass delays anticipated psilocybin readout, cuts staff

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Business Wire

a year ago

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Business Wire

a year ago

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Business Wire

a year ago

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Compass Pathways to participate in three investor conferences in September

GlobeNewswire

a year ago

Compass Pathways to participate in three investor conferences in September

Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks

TipRanks

a year ago

Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks

More promise for psilocybin in depression but safety remains a concern

Clinical Trials Arena

a year ago

More promise for psilocybin in depression but safety remains a concern

FDA Rejection of MDMA Therapy Isn’t End of Psychedelic-Drug Candidates

Barrons.com

a year ago

FDA Rejection of MDMA Therapy Isn’t End of Psychedelic-Drug Candidates

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

GlobeNewswire

a year ago

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript

Motley Fool

a year ago

Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript

Compass Pathways announces second quarter 2024 financial results and business highlights

GlobeNewswire

a year ago

Compass Pathways announces second quarter 2024 financial results and business highlights

Market Exclusive

a year ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Compass Pathways to announce second quarter financial results on August 1, 2024

GlobeNewswire

a year ago

Compass Pathways to announce second quarter financial results on August 1, 2024

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

GlobeNewswire

a year ago

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

GlobeNewswire

a year ago

Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Should You Buy the Dip on Compass Pathways Stock?

Motley Fool

a year ago

Should You Buy the Dip on Compass Pathways Stock?

Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.

Motley Fool

a year ago

Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.

After FDA setback, psychedelic drugmakers distance themselves from a pioneer

Washington Post

a year ago

After FDA setback, psychedelic drugmakers distance themselves from a pioneer

Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate

The Wall Street Journal

a year ago

Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate

These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring

Motley Fool

a year ago

These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring

COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript

Insider Monkey

2 years ago

COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript

Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript

Motley Fool

2 years ago

Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

2 years ago

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

GlobeNewswire

2 years ago

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Compass Pathways to announce first quarter financial results on May 8, 2024

GlobeNewswire

2 years ago

Compass Pathways to announce first quarter financial results on May 8, 2024

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

GlobeNewswire

2 years ago

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

GlobeNewswire

2 years ago

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire

2 years ago

Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference

20 Most Depressed Countries in Asia

Insider Monkey

2 years ago

20 Most Depressed Countries in Asia

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

GlobeNewswire

2 years ago

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

10 Alternatives to Antidepressant Medications

Insider Monkey

2 years ago

10 Alternatives to Antidepressant Medications

15 Highest Paying Jobs with a Psychology Degree

Insider Monkey

2 years ago

15 Highest Paying Jobs with a Psychology Degree

20 Countries with Most Antidepressant Users in the World

Insider Monkey

2 years ago

20 Countries with Most Antidepressant Users in the World

COMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

COMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Call Transcript

Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript

Motley Fool

2 years ago

Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript

GuruFocus.com

2 years ago

Compass Pathways PLC Reports Increased Annual Net Loss Amid Clinical Advancements

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

GlobeNewswire

2 years ago

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Penny Power Players: 3 Stocks to Watch in the Microcap Arena

InvestorPlace

2 years ago

Penny Power Players: 3 Stocks to Watch in the Microcap Arena

Compass Pathways to participate in upcoming TD Cowen investor conference

GlobeNewswire

2 years ago

Compass Pathways to participate in upcoming TD Cowen investor conference

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

GlobeNewswire

2 years ago

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

Mental Health Mavericks: 3 Stocks Changing the Game

InvestorPlace

2 years ago

Mental Health Mavericks: 3 Stocks Changing the Game

Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.

Motley Fool

2 years ago

Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.

As investors pile into psychedelics, idealism gives way to pharma economics

Associated Press Finance

2 years ago

As investors pile into psychedelics, idealism gives way to pharma economics

ELF Beauty, Palantir, Arm Holdings, Chipotle Headline Busy Earnings Calendar

Investor's Business Daily

2 years ago

ELF Beauty, Palantir, Arm Holdings, Chipotle Headline Busy Earnings Calendar

Is CAVA Group, Inc. (CAVA) Outperforming Other Retail-Wholesale Stocks This Year?

Zacks

2 years ago

Is CAVA Group, Inc. (CAVA) Outperforming Other Retail-Wholesale Stocks This Year?

Keller Williams Agrees to Pay $70 Million to Settle Antitrust Claims

The Wall Street Journal

2 years ago

Keller Williams Agrees to Pay $70 Million to Settle Antitrust Claims

Azul is once again recognized by its Successful Capital Optimization Plan concluded in 2023

PR Newswire

2 years ago

Azul is once again recognized by its Successful Capital Optimization Plan concluded in 2023

Compass Pathways to participate in upcoming Oppenheimer investor conference

GlobeNewswire

2 years ago

Compass Pathways to participate in upcoming Oppenheimer investor conference

Share on Social Networks: